Key result
Long-acting central sympatholytics manage afferent baroreflex failure by preventing hypertensive surges rather than normalizing BP.
Why the study?
Afferent baroreflex failure causes extreme blood pressure lability and is the most difficult form of hypertension to manage, yet little evidence-based data exist to guide treatment.
How should blood pressure be managed in patients with afferent baroreflex failure?
How should blood pressure be managed in patients with afferent baroreflex failure?
Management of afferent baroreflex failure should focus on improving quality of life using long-acting central sympatholytics rather than attempting to normalize blood pressure.
Supports long-acting central sympatholytics over short-acting clonidine; leaves open prospective validation in afferent baroreflex failure.
Afferent baroreflex failure is most often due to damage of the carotid sinus nerve because of neck surgery or radiation. The clinical picture is characterized by extreme blood pressure lability with severe hypertensive crises, hypotensive episodes, and orthostatic hypotension, making it the most difficult form of hypertension to manage. There is little evidence-based data to guide treatment. Recommendations rely on understanding the underlying pathophysiology, relevant clinical pharmacology and anecdotal experience. The goal of treatment should be improving quality of life rather than normalization of blood pressure which is rarely achievable. Long-acting central sympatholytics are the mainstay of treatment, used at the lowest doses that prevent the largest hypertensive surges. Short-acting clonidine should be avoided because of rebound hypertension but can be added to control residual hypertensive episodes, often triggered by mental stress or exertion. Hypotensive episodes can be managed with countermeasures and short acting pressor agents if necessary.
No takes yet. Share an insight, caveat, or question.
Biaggioni et al. (2019) conducted a review in Afferent baroreflex failure. Blood pressure management (long-acting central sympatholytics) was evaluated. Management of afferent baroreflex failure relies on long-acting central sympatholytics to prevent hypertensive surges, with a goal of improving quality of life rather than normalizing blood pressure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: